203 F.Supp.3d 412
D. Del.2016Background
- Vanda (owner/licensee) and Aventisub sued Roxane after Roxane filed an ANDA seeking approval to market generic iloperidone (FANAPT®) and sent paragraph IV notices alleging invalidity. The suits were consolidated and tried to the bench.
- Patents at issue: Reissue U.S. Patent No. RE39,198 ('198) claiming iloperidone (claim 3), and U.S. Patent No. 8,586,610 ('610) claiming methods of treating patients with iloperidone based on CYP2D6 genotyping and dose adjustments (claims 1–9, 11–13, 16).
- FANAPT® label and Roxane’s proposed ANDA label recommend genotyping for CYP2D6 poor metabolizers (PMs) and dose reduction (half-dose for PMs; 12 mg/day or less for PMs; up to 24 mg/day for non-PMs).
- Roxane conceded infringement of claim 3 of the '198 Patent if it is valid; parties disputed obviousness, §101 eligibility, written description for the '610, and infringement (including inducement and contributory infringement) regarding the '610.
- The court found all asserted claims valid, held Roxane’s proposed product would induce infringement of the '610 claims, but would not contribute to infringement; entered a permanent injunction preventing Roxane from marketing its ANDA product prior to the patents’ expirations.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Obviousness of '198 claim 3 | Patent non-obvious; skilled artisan would start from a known atypical antipsychotic, not the prior art compounds Roxane relies on | Claim obvious from prior art (Helsley/Duncan publications and related compounds); bioisosteric modification would be obvious | Court: '198 claim 3 valid — Roxane failed to overcome presumption of validity; hindsight and lack of motivating reason to select/modify the prior leads persuasive for nonobviousness |
| Obviousness of '610 (genotype-guided dosing) | Invention non-obvious; unpredictability of pharmacogenetics in vivo and clinical testing, Novartis abandoned development due to QTc risks; secondary considerations support nonobviousness | Prior art (in vitro metabolism studies, FDA expectations) would have motivated studying CYP2D6 and dose adjustments; routine clinical studies would yield the invention | Court: '610 claims not obvious — unpredictability and clinical testing requirements rebut obviousness; secondary factors support validity |
| §101 subject-matter eligibility of '610 | Claims are patent-eligible: they apply natural correlations in a specific, non-routine way (genotyping-guided dosing) and do not preempt genotyping generally | Claims directed to natural law (CYP2D6 effects on metabolism) with only routine steps (administering, determining); Mayo/Alice preclude patenting | Court: Claims implicate natural relationships but add sufficient inventive application (specific genotyping-directed dosing steps) so claims are patent-eligible |
| Infringement (inducement and contributory) of '610 | Roxane's proposed label instructs genotyping and dose reduction for CYP2D6 PMs, thus induces infringement; ANDA filing itself is an act of infringement | Label language is educational; physicians often phenotype or titrate to efficacy rather than genotype; substantial noninfringing uses exist so no inducement/contributory infringement | Court: Roxane's ANDA and proposed label induce infringement of asserted '610 claims (label instructs practice). No contributory infringement — substantial noninfringing uses exist (physicians may prescribe without genotyping). |
Key Cases Cited
- KSR Int'l Co. v. Teleflex, 550 U.S. 398 (superseding rigid TSM test for obviousness; allow common-sense combinations)
- Graham v. John Deere Co., 383 U.S. 1 (establishes Graham factors for obviousness)
- Mayo Collaborative Servs. v. Prometheus Labs., 566 U.S. 66 (laws of nature analysis; need "significantly more")
- Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (two-step §101 framework from Mayo applied)
- Diamond v. Diehr, 450 U.S. 175 (application of a law of nature in a claimed process can be patent-eligible)
- eBay Inc. v. MercExchange, 547 U.S. 388 (eBay factors for injunctive relief)
- AstraZeneca LP v. Apotex, 633 F.3d 1042 (label-based inducement analysis in ANDA context)
- Toshiba Corp. v. Imation Corp., 681 F.3d 1358 (distinguishing inducement and contributory infringement; substantial noninfringing uses)